EHA 2026 | Biological barriers preventing patients from achieving durable remission in CML
Timothy Hughes, MD, MBBS, FRACP, FRCPA, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia, comments on the challenge of achieving treatment-free remission (TFR) in chronic myeloid leukemia (CML), highlighting the persistence of leukemic stem cells and defects in immune control as major barriers. Prof. Hughes notes that the relative importance of these factors likely varies between patients and suggests that a patient-specific approach is needed to identify and target the limiting factor. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
